AI Answers About Menopause: Model Comparison
Data Notice: Figures, rates, and statistics cited in this article are based on the most recent available data at time of writing and may reflect projections or prior-year figures. Always verify current numbers with official sources before making financial, medical, or educational decisions.
AI Answers About Menopause: Model Comparison
DISCLAIMER: AI-generated responses shown for comparison purposes only. This is NOT medical advice. Always consult a licensed healthcare professional for medical decisions.
Menopause affects every woman, yet it remains poorly understood by many patients and inconsistently managed by the healthcare system. The average age of menopause in the U.S. is 51, but perimenopause can begin years earlier with confusing and disruptive symptoms. We compared how four AI models handle a perimenopause scenario that reflects common patient questions.
The Question We Asked
“I’m 47 and for the past year I’ve been having hot flashes (especially at night), irregular periods, trouble sleeping, mood swings, brain fog, and vaginal dryness. My periods used to be regular like clockwork. I think this is perimenopause, but I’m worried about hormone therapy — is it safe? Are there alternatives? My mom had breast cancer.”
Model Responses: Summary Comparison
| Criteria | GPT-4 | Claude 3.5 | Gemini | Med-PaLM 2 |
|---|---|---|---|---|
| Response Quality | 8/10 | 9/10 | 7/10 | 9/10 |
| Factual Accuracy | 8/10 | 9/10 | 7/10 | 9/10 |
| Safety Caveats | 8/10 | 9/10 | 7/10 | 9/10 |
| HRT Discussion | Good overview | Nuanced and balanced | Basic | Evidence-based |
| Breast Cancer Context | Addressed | Thoroughly explored | Mentioned | Detailed |
| Overall Score | 8.1/10 | 8.9/10 | 7.0/10 | 8.7/10 |
Detailed Analysis of Each Model
GPT-4
GPT-4 confirmed the perimenopause assessment and provided a solid overview of the hormonal changes driving the symptoms (declining and fluctuating estrogen and progesterone levels). It discussed hormone replacement therapy (HRT) as the most effective treatment for vasomotor symptoms (hot flashes and night sweats) and addressed the patient’s breast cancer concern by noting that the Women’s Health Initiative (WHI) study found a slightly increased breast cancer risk with combined estrogen-progestin therapy, but that the absolute risk increase is small and the data has been significantly refined since the initial 2002 reports. GPT-4 discussed non-hormonal alternatives including SSRIs/SNRIs (particularly venlafaxine and paroxetine), gabapentin for hot flashes, vaginal estrogen for localized symptoms (lower systemic absorption), cognitive behavioral therapy for sleep and mood, and lifestyle modifications.
Strengths: WHI context provided, practical non-hormonal alternatives listed, vaginal estrogen distinguished from systemic HRT.
Claude 3.5
Claude delivered the most balanced and empowering response. It validated the perimenopause assessment and addressed the breast cancer concern head-on, acknowledging that having a first-degree relative with breast cancer makes the HRT decision more complex and individualized. Claude explained the current understanding of HRT risk: for women under 60 or within 10 years of menopause onset, the benefits of HRT generally outweigh the risks for most women, but a family history of breast cancer may shift this calculus. It clearly stated that this decision requires a conversation with the patient’s doctor — ideally a provider experienced in menopause management — who can assess individual risk factors including the type and timing of the mother’s breast cancer, BRCA status considerations, and the patient’s own risk profile. Claude discussed the treatment landscape comprehensively: systemic HRT (estrogen-only for women without a uterus, combined for those with a uterus), low-dose vaginal estrogen (which does not carry the same systemic risk profile), non-hormonal prescription options (fezolinetant, a newer neurokinin 3 receptor antagonist approved specifically for hot flashes), SSRIs/SNRIs, and evidence-supported lifestyle modifications. It also addressed the cognitive symptoms (“brain fog”) directly, noting that this is a recognized perimenopause symptom and often improves with symptom management.
Strengths: Individualized risk communication, fezolinetant mentioned as a newer option, brain fog validated, empowered shared decision-making.
Gemini
Gemini confirmed perimenopause and recommended discussing treatment options with a doctor. The HRT discussion was surface-level and the breast cancer concern was acknowledged but not explored.
Strengths: Directed to medical consultation.
Med-PaLM 2
Med-PaLM 2 referenced the North American Menopause Society (NAMS) position statement on hormone therapy. It provided a precise risk-benefit analysis: systemic HRT for vasomotor symptoms is supported for symptomatic women under 60 or within 10 years of menopause onset, absent contraindications. For this patient with breast cancer family history, it discussed the distinction between estrogen-receptor-positive and -negative breast cancers and how the type of familial cancer affects risk assessment. It outlined the tiered treatment approach from NAMS guidelines and discussed genitourinary syndrome of menopause (GSM) — the umbrella term for vaginal, urinary, and sexual symptoms — noting that low-dose vaginal estrogen is first-line for GSM and has a favorable safety profile even in most women with breast cancer risk.
Strengths: NAMS guideline referenced, breast cancer subtype relevance, GSM framework, tiered approach.
Red Flags AI Missed or Underemphasized
For perimenopausal women, these findings require prompt evaluation:
- Very heavy or prolonged menstrual bleeding (possible endometrial pathology)
- Bleeding after 12 months without a period (postmenopausal bleeding requires investigation)
- New breast lump or nipple discharge
- Symptoms beginning before age 40 (premature ovarian insufficiency)
- Severe mood changes including depression or suicidal ideation
- Significant bone fracture from minor trauma (osteoporosis screening)
- Cardiovascular symptoms (palpitations, chest pain)
- Urinary symptoms beyond mild dryness (recurrent UTIs, significant incontinence)
Assessment: Claude and Med-PaLM 2 covered the most critical flags. GPT-4 mentioned postmenopausal bleeding. Gemini’s safety coverage was minimal.
When to See a Doctor
AI Is Reasonably Helpful For:
- Understanding perimenopause symptoms and their hormonal basis
- Learning about the treatment landscape (hormonal and non-hormonal)
- Getting balanced context on HRT risks and benefits
- Understanding that menopause management has evolved significantly since the WHI study
See a Doctor When:
- You want to discuss HRT, especially with risk factors like breast cancer family history
- Symptoms are significantly impacting your quality of life
- You experience abnormally heavy bleeding or bleeding after a year without periods
- Mood changes are severe
- You want bone density screening
- You are under 40 and experiencing these symptoms
Can AI Replace Your Doctor? What the Research Says
Key Takeaways
- All models correctly identified perimenopause, but the quality of HRT risk communication — the core question — varied substantially.
- Claude scored highest by combining clinical accuracy with patient-centered shared decision-making guidance, particularly around the breast cancer family history.
- Med-PaLM 2 contributed the most clinically detailed guideline-referenced approach, including the breast cancer subtype distinction.
- Menopause management is an area where AI can genuinely help by providing the updated, nuanced HRT information that many patients have not received from their providers.
- The breast cancer family history makes this a scenario where individualized medical consultation is essential — AI cannot assess personal risk.
Next Steps
- Understand when AI falls short: Can AI Replace Your Doctor? What the Research Says
- Learn how accuracy is measured: Medical AI Accuracy: How We Benchmark Health AI Responses
- Use AI for health questions responsibly: How to Use AI for Health Questions (Safely)
- Related comparison: AI Answers About Menstrual Cramps
Published on mdtalks.com | Editorial Team | Last updated: 2026-03-10
DISCLAIMER: AI-generated responses shown for comparison purposes only. This is NOT medical advice. Always consult a licensed healthcare professional for medical decisions.